Ga-DOTA-TATE

Phase 3Small molecule

Novartis

Ga-DOTA-TATE is one of 109 small molecule programs targeting Neuroendocrine Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmActive, not recruiting

Prostate CancerActive, not recruiting

GlioblastomaActive, not recruiting

Neuroendocrine NeoplasmPhase 3

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Ga-DOTA-TATE

Novartis

Phase 3

4 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Duragesic

CCephalon

Preclinical

1 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Metastatic Neuroendocrine Prostate Cancer

NCT06379217

Q3 2027

Phase 1Active, not recruiting

Glioblastoma

NCT05109728

Q1 2029

Phase 1/2Active, not recruiting

Newly Diagnosed

NCT05142696

Clinical

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Completed· Novartis logo

Novartis·Phase 3·NCT06240741·71 enrolled

Newly Diagnosed1 trial

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Active, not recruiting· Novartis logo

Novartis·Phase 1/2·NCT05142696·24 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06379217·31 enrolled

Glioblastoma1 trial

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT05109728·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ga-DOTA-TATE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-DOTA-TATE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-DOTA-TATE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Ga-DOTA-TATE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q1 2029

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

Newly Diagnosed1 trial

Metastatic Neuroendocrine Prostate Cancer1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News